Molgramostim biosimilar (Amoytop Biotech)

莫拉司亭生物类似药 (Amoytop Biotech)

Report date: 2025/09/10 16:16:41

Base Information

Drug NameMolgramostim biosimilar (Amoytop Biotech)
Drug Alias NamerHuGM-CSF (Xiamen Amoytop Biotech)莫拉司亭生物仿制药 (Amoytop Biotech)注射用人粒细胞巨噬细胞刺激因子Topleucon特尔立 +[6] 
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionGranulocyte-macrophage colony-stimulating factor receptor stimulants
TargetsGranulocyte-macrophage colony-stimulating factor receptor
Therapy Area/IndicationsLeukopeniaMyelodysplastic Syndromes
Global Approved IndicationsLeukopeniaMyelodysplastic Syndromes
Approved Indications in ChinaLeukopeniaMyelodysplastic Syndromes
Original Approved Country/TerritoryMainland China
Original Approved Date1998/01/01
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesXiamen Amoytop Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXiamen Amoytop Biotech Co Ltd
Inactive CompaniesN/A
Active IndicationsLeukopeniaMyelodysplastic Syndromes
Inactive IndicationsN/A

Other Information

ATC CodeL03AA03
Related LinksN/A